Brief: Immutep Announces First Participant Dosed In Phase I Study Of Imp761

Immutep

14/08/2024 13:43

Aug 14 (Reuters) - Immutep Ltd  IMM.AX :
    * IMMUTEP ANNOUNCES FIRST PARTICIPANT DOSED IN PHASE I STUDY
OF
IMP761, A FIRST IN CLASS AGONIST LAG-3 ANTIBODY
    * SAFETY DATA FROM FIRST-IN-HUMAN STUDY ANTICIPATED BY
YEAR-END
AND PHARMACOKINETICS AND PHARMACODYNAMICS DATA IN FIRST HALF
CY2025

Source text for Eikon:  ID:nGNX1kHTn4 
Further company coverage:  IMM.AX 

 ((Reuters.Briefs@thomsonreuters.com;))